围手术期地塞米松对胰十二指肠切除术后并发症的影响(PANDEX):一项实用性多中心随机对照试验的研究方案
PANDEX试验为研究者发起的多中心、前瞻性、随机、双盲、安慰剂对照的实用性研究,计划纳入300例择期胰十二指肠切除术患者,随机接受0.2 mg/kg地塞米松或生理盐水安慰剂,麻醉诱导后5分钟内静脉推注。主要结局为术后30天内综合并发症指数(CCI)评分,次要结局包括Clavien-Dindo≥3级主要并发症、术后胰瘘、胰切除术后急性胰腺炎、感染、非计划再剖腹术、术后住院时间及30天和90天死亡率。
要点
- PANDEX试验计划纳入300例择期胰十二指肠切除术患者,随机接受0.2 mg/kg地塞米松或生理盐水安慰剂。
- 主要结局为术后30天内综合并发症指数(CCI)评分。
- 次要结局包括Clavien-Dindo≥3级并发症、术后胰瘘、胰切除术后急性胰腺炎、感染、非计划再剖腹术、住院时间及30天和90天死亡率。
核心结论
- PANDEX试验是首个关于地塞米松对胰十二指肠切除术后并发症影响的随机对照试验,假设术中用地塞米松可降低术后并发症发生率并改善短期结局。
- 研究结果将指导围手术期地塞米松的使用,并有助于改善胰切除术后患者的临床管理。
研究设计与样本
- PANDEX试验为研究者发起的多中心、前瞻性、随机、双盲、安慰剂对照的实用性研究。
- 计划纳入300例拟接受择期胰十二指肠切除术的患者。
- 患者随机接受0.2 mg/kg地塞米松或生理盐水安慰剂,麻醉诱导后5分钟内静脉推注。
关键数值与推荐
- 主要结局为术后30天内综合并发症指数(CCI)评分。
- 次要结局包括Clavien-Dindo≥3级主要并发症、术后胰瘘(POPF)、胰切除术后急性胰腺炎(PPAP)、感染、非计划再剖腹术、术后住院时间、30天死亡率和90天死亡率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreaticoduodenectomy (PD) nowadays serves as a standard treatment for patients with disorders of the pancreas, intestine, and bile duct. Although the mortality rate of patients undergoing PD has decreased significantly, postoperative complication rates remain high. Dexamethasone, a synthetic glucocorticoid with potent anti-inflammatory and metabolic effects, has been proven to have a favorable effect on certain complications. However, the role it plays in post-pancreatectomy patients has not been systematically evaluated. The aim of this study is to assess the effect of dexamethasone on postoperative complications after PD. METHODS: The PANDEX trial is an investigator-initiated, multicentric, prospective, randomized, double-blinded, placebo-control, pragmatic study. The trial is designed to enroll 300 patients who are going to receive elective PD. Patients will be randomized to receive 0.2 mg/kg dexamethasone or saline placebo, administered as an intravenous bolus within 5 min after induction of anesthesia. The primary outcome is the Comprehensive Complication Index (CCI) score within 30 days after the operation. The secondary outcomes include postoperative major complications (Clavien-Dindo≥3), postoperative pancreatic fistula (POPF), post-pancreatectomy acute pancreatitis (PPAP), infection, and unexpected relaparotomy, as well as postoperative length of stay, 30-day mortality, and 90-day mortality. DISCUSSION: The PANDEX trial is the first randomized controlled trial concerning the effect of dexamethasone on postoperative complications of patients undergoing PD, with the hypothesis that the intraoperative use of dexamethasone can reduce the incidence of postoperative complications and improve short-term outcomes after PD. The results of the present study will guide the perioperative use of dexamethasone and help improve the clinical management of post-pancreatectomy patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT05567094. Registered on 30 September 30 2022.
引用
- Chen H, Wang Y, Wang C, et al. The effect of perioperative of dexamethasone on postoperative complications after pancreaticoduodenectomy (PANDEX): a study protocol for a pragmatic multicenter randomized controlled trial. Trials. 2023. PMID: 37660052. doi:10.1186/s13063-023-07571-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。